This product is suitable for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after crizotinib treatment or are intolerant to crizotinib.
The main ingredient of Ceritinib Capsules is Ceritinib, which is a kinase inhibitor. The drug achieves the effect of resisting tumor diseases by inhibiting the activity of targets such as ALK, ROS1 and TP53.
Let us work together to protect precious health